Molecular imaging of levodopa-induced dyskinesias

[1]  F. Niccolini,et al.  Molecular imaging of levodopa-induced dyskinesias , 2015, Cellular and Molecular Life Sciences.

[2]  F. Niccolini,et al.  Serotonin in Parkinson's disease , 2015, Behavioural Brain Research.

[3]  A. Björklund,et al.  Noradrenaline neuron degeneration contributes to motor impairments and development of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease , 2014, Experimental Neurology.

[4]  F. Niccolini,et al.  Dyskinesias in Parkinson's disease: views from positron emission tomography studies , 2014, European Journal of Neurology.

[5]  H. Sapru,et al.  Overexpression of the dopamine D3 receptor in the rat dorsal striatum induces dyskinetic behaviors , 2014, Behavioural Brain Research.

[6]  Anatol C. Kreitzer,et al.  Striatal Cholinergic Interneurons Drive GABA Release from Dopamine Terminals , 2014, Neuron.

[7]  F. Niccolini,et al.  Dopamine receptor mapping with PET imaging in Parkinson’s disease , 2014, Journal of Neurology.

[8]  F. Turkheimer,et al.  Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients. , 2014, The Journal of clinical investigation.

[9]  S. Duty,et al.  Therapeutic potential of targeting glutamate receptors in Parkinson’s disease , 2014, Journal of Neural Transmission.

[10]  A. Björklund,et al.  Anti-dyskinetic effect of anpirtoline in animal models of L-DOPA-induced dyskinesia , 2013, Neuroscience Research.

[11]  A. Destée,et al.  AFQ056 in Parkinson patients with levodopa‐induced dyskinesia: 13‐week, randomized, dose‐finding study , 2013, Movement disorders : official journal of the Movement Disorder Society.

[12]  M. Bencherif,et al.  Nicotinic Receptor Agonists Reduce l-DOPA–Induced Dyskinesias in a Monkey Model of Parkinson's Disease , 2013, The Journal of Pharmacology and Experimental Therapeutics.

[13]  M. Quik,et al.  Nicotine reduces established levodopa‐induced dyskinesias in a monkey model of Parkinson's disease , 2013, Movement disorders : official journal of the Movement Disorder Society.

[14]  S. Duty.  Targeting Glutamate Receptors to Tackle the Pathogenesis, Clinical Symptoms and Levodopa-Induced Dyskinesia Associated with Parkinson’s Disease , 2012, CNS Drugs.

[15]  Rajesh Pahwa,et al.  Treatment patterns and associated costs with Parkinson's disease levodopa induced dyskinesia , 2012, Journal of the Neurological Sciences.

[16]  W. Weiner,et al.  Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study) , 2012, Neurology.

[17]  M. Politis,et al.  Buspirone: What is it all about? , 2012, Brain Research.

[18]  A. Björklund,et al.  Serotonin Neuron Loss and Nonmotor Symptoms Continue in Parkinson’s Patients Treated with Dopamine Grafts , 2012, Science Translational Medicine.

[19]  R. Djaldetti,et al.  Patient and caregiver perceptions of the social impact of advanced Parkinson’s disease and dyskinesias , 2012, Journal of Neural Transmission.

[20]  Igor D. Grachev,et al.  Regional changes in type 1 cannabinoid receptor availability in Parkinson's disease in vivo , 2012, Neurobiology of Aging.

[21]  Marios Politis,et al.  Positron emission tomography imaging in neurological disorders , 2012, Journal of Neurology.

[22]  M. Stacy,et al.  Istradefylline for Parkinson's disease patients experiencing motor fluctuations: results of the KW-6002-US-018 study. , 2012, Parkinsonism & related disorders.

[23]  C. Parsons,et al.  Pharmacological characterization of MRZ-8676, a novel negative allosteric modulator of subtype 5 metabotropic glutamate receptors (mGluR5): focus on l-DOPA-induced dyskinesia , 2011, Journal of Neural Transmission.

[24]  O. Lindvall,et al.  Graft‐induced dyskinesias in Parkinson's disease: High striatal serotonin/dopamine transporter ratio , 2011, Movement disorders : official journal of the Movement Disorder Society.

[25]  S. Grady,et al.  Nicotine Reduces l-DOPA-Induced Dyskinesias by Acting at β2* Nicotinic Receptors , 2011, Journal of Pharmacology and Experimental Therapeutics.

[26]  Marios Politis,et al.  Positron emission tomography neuroimaging in Parkinson's disease. , 2011, American journal of translational research.

[27]  L. Grégoire,et al.  Metabotropic glutamate receptor type 5 in levodopa-induced motor complications , 2011, Neurobiology of Aging.

[28]  A. Nishi,et al.  Mechanisms for the Modulation of Dopamine D1 Receptor Signaling in Striatal Neurons , 2011, Front. Neuroanat..

[29]  Daniela Berg,et al.  Treatment of Levodopa-Induced Dyskinesias : Results of 2 Randomized Controlled Trials , 2011 .

[30]  C. Barnum,et al.  Behavioral and Cellular Modulation of l-DOPA-Induced Dyskinesia by β-Adrenoceptor Blockade in the 6-Hydroxydopamine-Lesioned Rat , 2011, Journal of Pharmacology and Experimental Therapeutics.

[31]  F. Turkheimer,et al.  Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease , 2011, Neurology.

[32]  L. Grégoire,et al.  The acute antiparkinsonian and antidyskinetic effect of AFQ056, a novel metabotropic glutamate receptor type 5 antagonist, in L-Dopa-treated parkinsonian monkeys. , 2011, Parkinsonism & related disorders.

[33]  Alexander Hammers,et al.  Glutamate NMDA receptor dysregulation in Parkinson's disease with dyskinesias. , 2011, Brain : a journal of neurology.

[34]  F. Micheli,et al.  Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial , 2011, The Lancet Neurology.

[35]  S. Kitamura,et al.  Adenosine A2A Receptors Measured with [11C]TMSX PET in the Striata of Parkinson's Disease Patients , 2011, PloS one.

[36]  P. Calabresi,et al.  Inhibition of phosphodiesterases rescues striatal long-term depression and reduces levodopa-induced dyskinesia. , 2011, Brain : a journal of neurology.

[37]  H. Koh,et al.  Positive association between striatal serotonin level and abnormal involuntary movements in chronic l-DOPA-treated hemiparkinsonian rats , 2011, Brain Research Bulletin.

[38]  M. Politis.  C O M M E N T a R Y Open Access , 2022 .

[39]  P. Calabresi,et al.  Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap , 2010, The Lancet Neurology.

[40]  Qin Li,et al.  A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys , 2010, Neurobiology of Disease.

[41]  Y. Mizuno,et al.  Clinical efficacy of istradefylline (KW‐6002) in Parkinson's disease: A randomized, controlled study , 2010, Movement disorders : official journal of the Movement Disorder Society.

[42]  Marios Politis,et al.  Serotonergic Neurons Mediate Dyskinesia Side Effects in Parkinson’s Patients with Neural Transplants , 2010, Science Translational Medicine.

[43]  J. Nutt,et al.  Dyskinesia and the antiparkinsonian response always temporally coincide , 2010, Neurology.

[44]  M. Cenci,et al.  l‐DOPA‐induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson’s disease: temporal and quantitative relationship to the expression of dyskinesia , 2010, Journal of neurochemistry.

[45]  K. Buck,et al.  The selective α1 adrenoceptor antagonist HEAT reduces L‐DOPA‐induced dyskinesia in a rat model of Parkinson's disease , 2010, Synapse.

[46]  M. Millan,et al.  The selective D3 receptor antagonist, S33084, improves parkinsonian-like motor dysfunction but does not affect l-DOPA-induced dyskinesia in 6-hydroxydopamine hemi-lesioned rats , 2010, Neuropharmacology.

[47]  K. Buck,et al.  The α2 adrenoceptor antagonist idazoxan alleviates l‐DOPA‐induced dyskinesia by reduction of striatal dopamine levels: an in vivo microdialysis study in 6‐hydroxydopamine‐lesioned rats , 2010, Journal of neurochemistry.

[48]  A. Björklund,et al.  Serotonin neuron-dependent and -independent reduction of dyskinesia by 5-HT1A and 5-HT1B receptor agonists in the rat Parkinson model , 2009, Experimental Neurology.

[49]  Mark Slifstein,et al.  In vivo quantification of regional dopamine‐D3 receptor binding potential of (+)‐PHNO: Studies in non‐human primates and transgenic mice , 2009, Synapse.

[50]  M. Millan,et al.  Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease , 2009, Neurobiology of Disease.

[51]  W. Danysz,et al.  Pharmacological Modulation of Glutamate Transmission in a Rat Model of l-DOPA-Induced Dyskinesia: Effects on Motor Behavior and Striatal Nuclear Signaling , 2009, Journal of Pharmacology and Experimental Therapeutics.

[52]  L. Grégoire,et al.  Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys. , 2009, Parkinsonism & related disorders.

[53]  Philippe Hantraye,et al.  Decrease of Nicotinic Receptors in the Nigrostriatal System in Parkinson's Disease , 2009, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[54]  T. Deak,et al.  Contribution of the striatum to the effects of 5‐HT1A receptor stimulation in L‐DOPA‐treated hemiparkinsonian rats , 2009, Journal of neuroscience research.

[55]  A. Newman,et al.  Evaluation of the D3 dopamine receptor selective antagonist PG01037 on l-dopa-dependent abnormal involuntary movements in rats , 2009, Neuropharmacology.

[56]  Alan A. Wilson,et al.  Decreased binding of the D3 dopamine receptor-preferring ligand [11C]-(+)-PHNO in drug-naive Parkinson's disease. , 2009, Brain : a journal of neurology.

[57]  R. Mach,et al.  Evaluation of D2 and D3 dopamine receptor selective compounds on l-dopa-dependent abnormal involuntary movements in rats , 2009, Neuropharmacology.

[58]  J. Gracies,et al.  Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in Parkinson's disease: A double blind video‐based analysis , 2009, Movement disorders : official journal of the Movement Disorder Society.

[59]  S. Fahn.  How do you treat motor complications in Parkinson's disease: Medicine, surgery, or both? , 2008, Annals of neurology.

[60]  C. Barnum,et al.  Striatal 5-HT1A receptor stimulation reduces D1 receptor-induced dyskinesia and improves movement in the hemiparkinsonian rat , 2008, Neuropharmacology.

[61]  A. Björklund,et al.  Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia. , 2008, Brain : a journal of neurology.

[62]  Takaichi Fukuda,et al.  Distinct Roles of PDE4 and PDE10A in the Regulation of cAMP/PKA Signaling in the Striatum , 2008, The Journal of Neuroscience.

[63]  M. Quik,et al.  Continuous and Intermittent Nicotine Treatment Reduces l-3,4-Dihydroxyphenylalanine (l-DOPA)-Induced Dyskinesias in a Rat Model of Parkinson's Disease , 2008, Journal of Pharmacology and Experimental Therapeutics.

[64]  G. Bernardi,et al.  Lowered cAMP and cGMP signalling in the brain during levodopa‐induced dyskinesias in hemiparkinsonian rats: new aspects in the pathogenetic mechanisms , 2008, The European journal of neuroscience.

[65]  M. Shoji,et al.  Reuptake of L‐DOPA‐derived extracellular DA in the striatum of a rodent model of Parkinson's disease via norepinephrine transporter , 2008, Synapse.

[66]  L. Grégoire,et al.  mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys , 2008, Neurobiology of Aging.

[67]  R. Moratalla,et al.  Expression and Function of CB1 Receptor in the Rat Striatum: Localization and Effects on D1 and D2 Dopamine Receptor-Mediated Motor Behaviors , 2008, Neuropsychopharmacology.

[68]  J. Nutt,et al.  Placebo influences on dyskinesia in Parkinson's disease , 2008, Movement disorders : official journal of the Movement Disorder Society.

[69]  P. Calabresi,et al.  l-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation , 2008, Neurobiology of Disease.

[70]  L. Grégoire,et al.  Basal ganglia group II metabotropic glutamate receptors specific binding in non-human primate model of L-Dopa-induced dyskinesias , 2008, Neuropharmacology.

[71]  D. D. Di Monte,et al.  Nicotine reduces levodopa‐induced dyskinesias in lesioned monkeys , 2007, Annals of neurology.

[72]  Vikas Gupta,et al.  The partial 5-HT1A agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy , 2007, Pharmacology Biochemistry and Behavior.

[73]  C. Goetz,et al.  Levodopa‐induced dyskinesias , 2007, Movement disorders : official journal of the Movement Disorder Society.

[74]  Anders Björklund,et al.  Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. , 2007, Brain : a journal of neurology.

[75]  W. Danysz,et al.  Modulation of l-DOPA-induced abnormal involuntary movements by clinically tested compounds: Further validation of the rat dyskinesia model , 2007, Behavioural Brain Research.

[76]  W. Danysz,et al.  Antagonism of metabotropic glutamate receptor type 5 attenuates l‐DOPA‐induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson’s disease , 2007, Journal of neurochemistry.

[77]  O. Rascol,et al.  Sarizotan as a treatment for dyskinesias in Parkinson's disease: A double‐blind placebo‐controlled trial , 2007, Movement disorders : official journal of the Movement Disorder Society.

[78]  Yen F. Tai,et al.  Clinical correlates of levodopa-induced dopamine release in Parkinson disease , 2006, Neurology.

[79]  P. Bédard,et al.  Opioids and motor complications in Parkinson's disease. , 2006, Trends in pharmacological sciences.

[80]  T. Di Paolo,et al.  Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: Effect on adenosine A2A receptors , 2006, Synapse.

[81]  F. Menniti,et al.  Phosphodiesterases in the CNS: targets for drug development , 2006, Nature Reviews Drug Discovery.

[82]  J. Obeso,et al.  Drug Insight: continuous dopaminergic stimulation in the treatment of Parkinson's disease , 2006, Nature Clinical Practice Neurology.

[83]  E. Bézard,et al.  Increased slow oscillatory activity in substantia nigra pars reticulata triggers abnormal involuntary movements in the 6-OHDA-lesioned rat in the presence of excessive extracelullar striatal dopamine , 2006, Neurobiology of Disease.

[84]  W. Danysz,et al.  Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease , 2006, Brain Research Bulletin.

[85]  J. Bucerius,et al.  In vitro evaluation of nicotinic acetylcholine receptors with 2-[18F]F-A85380 in Parkinson's disease. , 2006, Nuclear medicine and biology.

[86]  P. Jeffrey Conn,et al.  Metabotropic glutamate receptors in the basal ganglia motor circuit , 2005, Nature Reviews Neuroscience.

[87]  K. Nagata,et al.  Serotonergic hyperinnervation into the dopaminergic denervated striatum compensates for dopamine conversion from exogenously administered l-DOPA , 2005, Brain Research.

[88]  E. Bézard,et al.  Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors. , 2005, Parkinsonism & related disorders.

[89]  L. Mignon,et al.  8-Hydroxy-2-(di-n-propylamino)tetralin reduces striatal glutamate in an animal model of Parkinson's disease , 2005, Neuroreport.

[90]  Joseph Jankovic,et al.  Motor fluctuations and dyskinesias in Parkinson's disease: Clinical manifestations , 2005, Movement disorders : official journal of the Movement Disorder Society.

[91]  Vesna Sossi,et al.  Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. , 2004, Brain : a journal of neurology.

[92]  E. Růžička,et al.  Survey on cannabis use in Parkinson's disease: Subjective improvement of motor symptoms , 2004, Movement disorders : official journal of the Movement Disorder Society.

[93]  O. Hornykiewicz,et al.  Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias. , 2004, Brain : a journal of neurology.

[94]  L. Forno,et al.  Loss of α‐conotoxinMII‐ and A85380‐sensitive nicotinic receptors in Parkinson's disease striatum , 2004 .

[95]  T. Chase,et al.  A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson’s disease , 2003, Experimental Neurology.

[96]  J. Brotchie,et al.  Fipamezole (JP‐1730) is a potent α2 adrenergic receptor antagonist that reduces levodopa‐induced dyskinesia in the MPTP‐lesioned primate model of Parkinson's disease , 2003, Movement disorders : official journal of the Movement Disorder Society.

[97]  D. Watanabe,et al.  Impairment of reward-related learning by cholinergic cell ablation in the striatum , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[98]  Thomas Boraud,et al.  Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function , 2003, Nature Medicine.

[99]  Paul Greengard,et al.  Loss of bidirectional striatal synaptic plasticity in L-DOPA–induced dyskinesia , 2003, Nature Neuroscience.

[100]  C. Clarke,et al.  Amantadine for dyskinesia in Parkinson's disease. , 2003, The Cochrane database of systematic reviews.

[101]  Chris Zarow,et al.  Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. , 2003, Archives of neurology.

[102]  A. Stoessl,et al.  Effects of oligonucleotide antisense to dopamine D3 receptor mRNA in a rodent model of behavioural sensitization to levodopa , 2003, Neuroscience.

[103]  P. Calabresi,et al.  Striatal metabotropic glutamate receptor function following experimental parkinsonism and chronic levodopa treatment. , 2002, Brain : a journal of neurology.

[104]  Charles J. Wilson,et al.  Cholinergic interneuron characteristics and nicotinic properties in the striatum. , 2002, Journal of neurobiology.

[105]  Stanley Fahn,et al.  Dyskinesia after fetal cell transplantation for parkinsonism: A PET study , 2002, Annals of neurology.

[106]  A. Björklund,et al.  Dyskinesias following neural transplantation in Parkinson's disease , 2002, Nature Neuroscience.

[107]  J. Brotchie,et al.  Cannabinoids reduce levodopa-induced dyskinesia in Parkinson’s disease: A pilot study , 2001, Neurology.

[108]  T. Chase,et al.  Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models , 2001, Neurology.

[109]  V. Sossi,et al.  Apomorphine-Induced Changes in Synaptic Dopamine Levels: Positron Emission Tomography Evidence for Presynaptic Inhibition , 2001, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[110]  R. E. Adams,et al.  Autoregulation of cerebral blood flow surrounding acute (6 to 22 hours) intracerebral hemorrhage , 2001, Neurology.

[111]  Y. Agid,et al.  Idazoxan, an alpha‐2 antagonist, and L‐DOPA‐induced dyskinesias in patients with Parkinson's disease , 2001, Movement disorders : official journal of the Movement Disorder Society.

[112]  J. Brotchie,et al.  Neural mechanisms underlying peak‐dose dyskinesia induced by levodopa and apomorphine are distinct: Evidence from the effects of the alpha2 adrenoceptor antagonist idazoxan , 2001, Movement disorders : official journal of the Movement Disorder Society.

[113]  M. Muenter,et al.  Frequency of levodopa‐related dyskinesias and motor fluctuations as estimated from the cumulative literature , 2001, Movement disorders : official journal of the Movement Disorder Society.

[114]  M Schulzer,et al.  Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover. , 2001, Annals of neurology.

[115]  Vesna Sossi,et al.  Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover , 2001 .

[116]  W. Poewe,et al.  Beneficial effects of amantadine on L‐dopa‐induced dyskinesias in Parkinson's disease , 2000, Movement disorders : official journal of the Movement Disorder Society.

[117]  M E Phelps,et al.  Positron emission tomography provides molecular imaging of biological processes. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[118]  Josemir W Sander,et al.  The incidence and lifetime prevalence of neurological disorders in a prospective community-based study in the UK. , 2000, Brain : a journal of neurology.

[119]  B. Snow,et al.  The Effect of Amantadine on Levodopa-induced Dyskinesias in Parkinson's Disease: A Double-blind, Placebo-controlled Study , 2000, Clinical neuropharmacology.

[120]  P. Jenner,et al.  Alterations in preproenkephalin and adenosine‐2a receptor mRNA, but not preprotachykinin mRNA correlate with occurrence of dyskinesia in normal monkeys chronically treated with l‐DOPA , 2000, The European journal of neuroscience.

[121]  P. Bédard,et al.  Noradrenoceptor antagonism with idazoxan improves l-dopa-induced dyskinesias in MPTP monkeys , 2000, Naunyn-Schmiedeberg's Archives of Pharmacology.

[122]  P. Greengard,et al.  Beyond the Dopamine Receptor: Review the DARPP-32/Protein Phosphatase-1 Cascade , 1999 .

[123]  T. Suda,et al.  Role of serotonergic neurons in L-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats. , 1999, Neuroreport.

[124]  L. Metman,et al.  Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease , 1998, Neurology.

[125]  L. Niles,et al.  Sensitization of G Protein‐Coupled Benzodiazepine Receptors in the Striatum of 6‐Hydroxydopamine‐Lesioned Rats , 1997, Journal of neurochemistry.

[126]  D J Brooks,et al.  Alterations in opioid receptor binding in Parkinson's disease patients with levodopa‐induced dyskinesias , 1997, Annals of neurology.

[127]  P. Sokoloff,et al.  Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[128]  R. Faull,et al.  Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain , 1997, Neuroscience.

[129]  Y. Agid,et al.  Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease , 1996, Neurology.

[130]  R. Arai,et al.  l-DOPA is converted to dopamine in serotonergic fibers of the striatum of the rat: a double-labeling immunofluorescence study , 1995, Neuroscience Letters.

[131]  R. Arai,et al.  Immunohistochemical evidence that central serotonin neurons produce dopamine from exogenousl-DOPA in the rat, with reference to the involvement of aromaticl-amino acid decar☐ylase , 1994, Brain Research.

[132]  N. Weiner,et al.  Dopaminergic functional supersensitivity: effects of chronic L-dopa and carbidopa treatment in an animal model of Parkinson's disease. , 1993, The Journal of pharmacology and experimental therapeutics.

[133]  P. Bédard,et al.  Effect of nondopaminergic drugs on L-dopa-induced dyskinesias in MPTP-treated monkeys. , 1993, Clinical neuropharmacology.

[134]  J. Vanderhaeghen,et al.  Localization of cannabinoid receptor in the human developing and adult basal ganglia. Higher levels in the striatonigral neurons , 1992, Neuroscience Letters.

[135]  Wade K. Smith,et al.  Disease‐specific patterns of locus coeruleus cell loss , 1992, Annals of neurology.

[136]  M. Martres,et al.  Identification, characterization, and localization of the dopamine D3 receptor in rat brain using 7-[3H]hydroxy-N,N-di-n-propyl-2-aminotetralin. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[137]  F. Colpaert,et al.  Effects of locus coeruleus lesions on parkinsonian signs, striatal dopamine and substantia nigra cell loss after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in monkeys: A possible role for the locus coeruleus in the progression of Parkinson's disease , 1991, Neuroscience.

[138]  J. Rinne,et al.  A postmortem study of brain nicotinic receptors in Parkinson's and Alzheimer's disease , 1991, Brain Research.

[139]  Alan A. Wilson,et al.  Quantification of Human Opiate Receptor Concentration and Affinity Using High and Low Specific Activity [11C]Diprenorphine and Positron Emission Tomography , 1991, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[140]  M. Herkenham,et al.  Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study , 1991, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[141]  Bruno Giros,et al.  Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics , 1990, Nature.

[142]  I. Kopin,et al.  Effects of L-Dopa on Efflux of Cerebral Monoamines from Synaptosomes , 1971, Nature.

[143]  A. Björklund,et al.  Long-term clinical outcome of fetal cell transplantation for Parkinson disease: two case reports. , 2014, JAMA neurology.

[144]  J. Girault.  Integrating neurotransmission in striatal medium spiny neurons. , 2012, Advances in experimental medicine and biology.

[145]  P. Piccini,et al.  In vivo imaging of the integration and function of nigral grafts in clinical trials. , 2012, Progress in brain research.

[146]  P. Piccini,et al.  Functional Neural Transplantation III , 2012 .

[147]  P. Piccini,et al.  Brain imaging after neural transplantation. , 2010, Progress in brain research.

[148]  M. Morelli,et al.  Adenosine A2A receptors and Parkinson's disease. , 2009, Handbook of experimental pharmacology.

[149]  A. Nilsson.  Pathophysiology of L-DOPA-Induced Dyskinesia in Parkinson's Disease , 2009 .

[150]  L. Forno,et al.  Loss of alpha-conotoxinMII- and A85380-sensitive nicotinic receptors in Parkinson's disease striatum. , 2004, Journal of neurochemistry.

[151]  M. Onofrj,et al.  Duration of amantadine benefit on dyskinesia of severe Parkinson's disease. , 2004, Journal of neurology, neurosurgery, and psychiatry.